Disc Medicine, Inc. (NASDAQ:IRON – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the eight research firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 12 month […]
Disc Medicine (NASDAQ:IRON – Free Report) had its price target boosted by Stifel Nicolaus from $71.00 to $73.00 in a research note released on Monday, Benzinga reports. Stifel Nicolaus currently has a buy rating on the stock. IRON has been the subject of several other research reports. Wedbush reiterated an outperform rating and set a […]
Raymond James reissued their outperform rating on shares of Disc Medicine (NASDAQ:IRON – Free Report) in a report issued on Monday morning, Marketbeat reports. The brokerage currently has a $40.00 target price on the stock, down from their prior target price of $75.00. A number of other research firms have also recently commented on IRON. […]
Wedbush restated their outperform rating on shares of Disc Medicine (NASDAQ:IRON – Free Report) in a research report released on Monday morning, RTT News reports. The brokerage currently has a $43.00 target price on the stock, down from their prior target price of $84.00. Wedbush also issued estimates for Disc Medicine’s Q4 2024 earnings at […]
Wedbush reaffirmed their outperform rating on shares of Disc Medicine (NASDAQ:IRON – Free Report) in a report issued on Monday morning, RTT News reports. Wedbush currently has a $43.00 price objective on the stock, down from their prior price objective of $84.00. Wedbush also issued estimates for Disc Medicine’s Q4 2024 earnings at ($1.19) EPS, […]